http://www.clinicaltrials.gov/ct/sho...240916?order=3
This is an open-label immunogenicity and safety study of live attenuated Measles Vaccine (Attenuvax) and Measles-Mumps-Rubella (MMR-II) vaccine administered to healthy children at 6, 9, or 12 months of age. Both vaccines are licensed in the U.S. for use in infants.
The purpose of the study is to evaluate the acquisition of measles specific CD4 T cell immunity elicited by vaccination in relation to age at vaccination and to evaluate the safety of an early two dose measles vaccine regimen in infancy.
210 healthy children will be randomized to one of three vaccine cohorts.
Cohort 1 will receive Attenuvax at 6 months of age followed by MMR-II at 12 months. Cohort 2 will receive Attenuvax at 9 months of age followed by MMR-II at 12 months. Cohort 3 will receive MMR-II at 12 months.
All children will be followed through 18 months of age for development of measles-specific immune responses.
.
This is an open-label immunogenicity and safety study of live attenuated Measles Vaccine (Attenuvax) and Measles-Mumps-Rubella (MMR-II) vaccine administered to healthy children at 6, 9, or 12 months of age. Both vaccines are licensed in the U.S. for use in infants.
The purpose of the study is to evaluate the acquisition of measles specific CD4 T cell immunity elicited by vaccination in relation to age at vaccination and to evaluate the safety of an early two dose measles vaccine regimen in infancy.
210 healthy children will be randomized to one of three vaccine cohorts.
Cohort 1 will receive Attenuvax at 6 months of age followed by MMR-II at 12 months. Cohort 2 will receive Attenuvax at 9 months of age followed by MMR-II at 12 months. Cohort 3 will receive MMR-II at 12 months.
All children will be followed through 18 months of age for development of measles-specific immune responses.
.







:








